• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AnaptysBio, Inc. - Common Stock (NQ:ANAB)

44.67 +0.87 (+1.99%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 591,811
Open 42.75
Bid (Size) 25.66 (100)
Ask (Size) 48.00 (200)
Prev. Close 43.80
Today's Range 42.50 - 46.27
52wk Range 12.21 - 52.47
Shares Outstanding 27,433,359
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary
January 08, 2026
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 06, 2026
From AnaptysBio, Inc.
Via GlobeNewswire

Performance

YTD
-0.6%
-0.6%
1 Month
+2.0%
+2.0%
3 Month
+40.6%
+40.6%
6 Month
+71.2%
+71.2%
1 Year
+211.1%
+211.1%

More News

Read More
News headline image
AnaptysBio Inc (NASDAQ:ANAB) Meets Minervini Trend Template with High-Growth Momentum ↗
December 20, 2025
Via Chartmill
News headline image
Anaptys Announces Participation in December Investor Conferences
November 25, 2025
From AnaptysBio, Inc.
Via GlobeNewswire
ANAB Stock Falls After It Sues GSK Unit Tesaro Again, Claims Fresh Breach Of 2014 Deal ↗
November 21, 2025
Via Stocktwits
Topics Lawsuit
AnaptysBio Stock Gets A Price Target Hike After Announcing Plan To Separate Royalty, Biopharma Businesses – Check Out The New Level ↗
September 30, 2025
Via Stocktwits
News headline image
AnaptysBio Inc (NASDAQ:ANAB) Screens as a High-Growth Momentum Leader ↗
November 22, 2025
Via Chartmill
News headline image
Anaptys Announces $100 Million Stock Repurchase Plan
November 21, 2025
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary
November 21, 2025
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
ANAPTYSBIO INC (NASDAQ:ANAB) Shows High-Growth Momentum and Positive Technical Setup ↗
November 13, 2025
Via Chartmill
News headline image
AnaptysBio To Save $10 Million After Discontinuing Ulcerative Colitis Study ↗
November 10, 2025
Via Benzinga
News headline image
Why AnaptysBio Stock Plummeted, Reversing A 70% Monthlong Run ↗
November 10, 2025
Via Investor's Business Daily
News headline image
Anaptys Announces Participation in November Investor Conferences
November 04, 2025
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis
November 10, 2025
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update
November 04, 2025
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation
October 29, 2025
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025
October 13, 2025
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Wall Street Climbs Despite Shutdown Risk — Pfizer and CoreWeave Shine Bright ↗
October 01, 2025
Via Chartmill
Topics Artificial Intelligence
News headline image
Here are the top movers in Tuesday's session. ↗
September 30, 2025
Via Chartmill
News headline image
AnaptysBio Charts Path To Split Into Two Public Companies By 2026 ↗
September 30, 2025
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
September 30, 2025
Via Benzinga
News headline image
United Natural Foods Posts Upbeat Results, Joins AnaptysBio, Semtech, UiPath And Other Big Stocks Moving Higher On Tuesday ↗
September 30, 2025
Via Benzinga
News headline image
Tuesday's session: gap up and gap down stocks ↗
September 30, 2025
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
September 29, 2025
Via Benzinga
News headline image
Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026
September 29, 2025
From AnaptysBio, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is AnaptysBio, Inc. - Common Stock publicly traded?
Yes, AnaptysBio, Inc. - Common Stock is publicly traded.
What exchange does AnaptysBio, Inc. - Common Stock trade on?
AnaptysBio, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for AnaptysBio, Inc. - Common Stock?
The ticker symbol for AnaptysBio, Inc. - Common Stock is ANAB on the Nasdaq Stock Market
What is the current price of AnaptysBio, Inc. - Common Stock?
The current price of AnaptysBio, Inc. - Common Stock is 44.67
When was AnaptysBio, Inc. - Common Stock last traded?
The last trade of AnaptysBio, Inc. - Common Stock was at 01/09/26 04:00 PM ET
What is the market capitalization of AnaptysBio, Inc. - Common Stock?
The market capitalization of AnaptysBio, Inc. - Common Stock is 1.23B
How many shares of AnaptysBio, Inc. - Common Stock are outstanding?
AnaptysBio, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap